ASCO21: Novartis’ prostate cancer radiotherapy extends survivalNovartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men Share XASCO21: Novartis’ prostate cancer radiotherapy extends survivalhttps://pharmaphorum.com/news/asco21-novartis-prostate-cancer-radiotherapy-extends-survival/
